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Summary
We have previously reported that ES-62, a molecule secreted by the para-
sitic filarial nematode Acanthocheilonema viteae, protects mice from devel-
oping collagen-induced arthritis (CIA). Together with increasing evidence
that worm infection may protect against autoimmune conditions, this
raises the possibility that ES-62 may have therapeutic potential in rheu-
matoid arthritis and hence, it is important to fully understand its mecha-
nism of action. To this end, we have established to date that ES-62
protection in CIA is associated with suppressed T helper type 1 (Th1)/
Th17 responses, reduced collagen-specific IgG2a antibodies and increased
interleukin-10 (IL-10) production by splenocytes. IL-10-producing regula-
tory B cells have been proposed to suppress pathogenic Th1/Th17
responses in CIA: interestingly therefore, although the levels of IL-10-pro-
ducing B cells were decreased in the spleens of mice with CIA, ES-62 was
found to restore these to the levels found in naive mice. In addition,
exposure to ES-62 decreased effector B-cell, particularly plasma cell, infil-
tration of the joints, and such infiltrating B cells showed dramatically
reduced levels of Toll-like receptor 4 and the activation markers, CD80
and CD86. Collectively, this induction of hyporesponsiveness of effector
B-cell responses, in the context of the resetting of the levels of IL-10-
producing B cells, is suggestive of a modulation of the balance between
effector and regulatory B-cell responses that may contribute to ES-62-
mediated suppression of CIA-associated inflammation and inhibition of
production of pathogenic collagen-specific IgG2a antibodies.
Keywords: ES-62; interleukin-10-producing B cells; parasitic helminths;
rheumatoid arthritis.
Introduction
The prevalence of autoimmune disease in the developing
world inversely correlates with parasitic helminth infec-
tion,1,2 an apparent serendipitous side-effect of the ability
of worms to secrete anti-inflammatory molecules that
modulate the host immune system and promote parasite
survival. Such epidemiological evidence has understand-
ably generated interest in the therapeutic potential of
such immunomodulators and also in their use as tools to
dissect the pathogenic mechanisms underlying inflamma-
tory disorders.3 We have previously shown that one such
immunomodulator, ES-62, a phosphorylcholine-contain-
ing glycoprotein, secreted by the filarial nematode
Acanthocheilonema viteae, is protective in the mouse
collagen-induced arthritis (CIA) model of rheumatoid
arthritis (RA) by acting to suppress pathogenic T helper
type 1 (Th1)/Th17 responses.4 The success of rituximab
as a therapy for autoimmune disease has refocused inter-
est on the pathogenic and protective roles of B cells in
RA5 with recent studies highlighting the importance of
interleukin-10 (IL-10)-producing regulatory B (Breg) cells
in the prevention and amelioration of CIA and also
antigen-induced arthritis (AIA), via the suppression of
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Th1/Th17 responses and the promotion of type 1 regula-
tory T (Tr1) and regulatory T (Treg) cell differentiation.5–8
Interestingly, therefore, we have found that while exposure
to ES-62 results in enhanced spontaneous ex vivo produc-
tion of IL-10 by splenocytes from mice with CIA, it induces
hyporesponsiveness of normal and CIA-derived splenic B
cells and reduces the levels of pathogenic collagen-specific
IgG2a antibodies.9 Relating to this, we now show that the
protective effects of ES-62 in CIA are associated with resto-
ration of the levels of IL-10-producing B cells and suppres-
sion of the infiltration of activated plasma cells into the
joints, perhaps suggesting that ES-62 may act, at least in
part, to modulate the balance between effector and regula-
tory B-cell responses in this mouse model of RA.
Materials and methods
Collagen-induced arthritis
Animals were maintained in the Biological Services Units
in accordance with the Home Office UK Licences PPL60/
3580, PPL60/3791, PPL60/4300 and PIL60/9576, PIL60/
12183 and PIL60/12950 and the Ethics Review Boards of
the Universities of Glasgow and Strathclyde. Arthritis was
induced in male DBA/1 mice (8–10 weeks old; Harlan
Olac, Bicester, UK) by intradermal immunization with
bovine type II collagen (MD Biosciences, Zurich, Switzerland)
in complete Freund’s adjuvant on day 0 and in PBS on
day 21. Mice with CIA were treated with purified endo-
toxin-free ES-62 (2 lg/dose) or PBS subcutaneously on
days 2, 0 and 21 and cells were recovered from joints10
as previously described.4,9,11 All analysis was performed at
cull (day 28) and represents data from at least two inde-
pendent experiments.
Ex vivo analysis
Splenocytes and draining lymph node (DLN) cells (106/ml)
were analysed for B-cell IL-10 responses by stimulating
with or without 50 ng/ml PMA (Sigma-Aldrich, Poole,
UK) plus 500 ng/ml ionomycin (Sigma-Aldrich) and
10 lg/ml lipopolysaccharide (Escherichia coli O111:B4;
Sigma-Aldrich) for 1 hr before addition of 10 lg/ml brefel-
din A (Sigma-Aldrich) for 5 hr at 37° with 5% CO2.
12,13
Lymphocyte subsets were analysed by flow cytometry of
unstimulated cells adapting the gating strategy (Fig. 1)
of Allman and Pillai14 using antibodies specific for the
following markers (with relevant fluorochrome): CD5/Bio-
tin-svE450; CD8/Biotin-sv peridinin chlorophyll protein
streptavidin (svPerCP) (both BD Pharmingen, Franklin
Lakes, NJ); AA4.1/allophycocyanin (APC); B220/BV421;
CD11c/Biotin-svPerCP; CD138/phycoerythrin (PE); CD19/
AF700; CD1d/PE; CD23/PE-Cy7; CD24/PerCP-Cy5.5;
CD4/Biotin-svPerCP; CD43/PE-Cy7; IgD/PerCP-Cy5.5;
IgM/APC-Cy7; F4/80/Biotin-svPerCP (all BioLegend, San
Diego, CA), and CD21/E450 and GL7/E450 (both eBio-
science, San Diego, CA). Additional phenotypic markers
were labelled using anti-Toll-like receptor 4 (TLR4)-APC
(R&D Systems, Abingdon, UK), anti-BAFF-R-FITC (eBio-
science), anti-CD4-PE, anti-CD80-PerCP/Cy5.5 or anti-
CD86-AF488 (BioLegend) antibodies before the cells were
fixed and permeabilized using BioLegend products and proto-
cols. Stimulated cells were then labelled using anti-IL-10-
APC (BioLegend) antibodies for 30 min before flow cytom-
etry to detect IL-10-producing B cells. Data analysis gates
were set according to appropriate isotype controls. Dead
cells were identified and excluded from analysis using the
Live/Dead Fixable Dead Cell Stain (Aqua) using the man-
ufacturer’s suggested protocol (Invitrogen, Paisley, UK).
Statistics
Parametric data were analysed by the Student’s t-test or
by one-way analysis of variance (ANOVA) while non-para-
metric data were analysed by Mann–Whitney and Krus-
kal–Wallis tests where *P < 005, **P < 001 and
***P < 0001.
Results
ES-62 reduces the levels of germinal centre (GC) B
cells in the spleens of mice with CIA
We investigated whether ES-62-mediated protection
against CIA (Fig. 2a) correlated with modulation of B-cell
populations (Fig. 1). There was no significant modulation
by the helminth product of either the proportion or num-
ber of CD19+ B cells in the spleen [Fig. 2b; numbers
(9 106)  SEM: Naive, 2513  226; PBS, 2686  176;
ES-62, 2827  268] or LN (data not shown) and consis-
tent with this, no significant changes were observed in the
transitional (T1–T3), marginal zone precursor or marginal
zone populations in the spleen (Fig. 2c,d and results not
shown). However, ES-62 significantly increased the levels
of CD19+ CD21low CD23high follicular B cells (Fo; Fig. 2c,
d) and further analysis showed that although exposure to
ES-62 had no effect on follicular type-2 (Fo2) B cells
(results not shown), it significantly increased the levels of
follicular type-1 B2 cells (Fo1; Fig. 2e; numbers
(9 106)  SEM: Naive, 558  082; PBS, 608  064;
ES-62, 797  091) in the spleen. The increase in Fo1 B
cells was associated with corresponding reductions in GC B
cells (Fig. 2f; numbers (9 106)  SEM are: PBS, 628 
136; ES-62, 295  039) and CD3+ CD4+ ICOS+
CXCR5+ follicular helper T cells [from 242 (PBS) to
149% of live splenocytes exposed to ES-62] in the spleen.
By contrast, ES-62 had no effect on the levels of
CD19+ B220+ IgM IgD IgG+ cells, which may represent
a subset of memory B cells (results not shown). Collec-
tively, these data suggest that ES-62 may act to reduce the
ª 2013 The Authors. Immunology published by John Wiley & Sons Ltd. Immunology, 141, 457–466458
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Figure 1. Gating strategy for analysis of B-cell subsets and phenotyping of populations. This is a modification of that based on the peripheral B
cell phenotypic markers defined by Allman and Pillai.14 T1: CD19+ CD93+ CD21int CD23 IgDlow/ IgMhigh; T2:
CD19+ CD93+ CD21int CD23+ IgDhigh IgMhigh; T3: CD19+ CD93+ CD21int CD23+ IgDhigh IgMlow; marginal zone precursor (MZP):
CD19+ CD93 CD21high CD23+ CD1dhigh IgDhigh IgMhigh; marginal zone (MZ): CD19+ CD93 CD21high CD23 CD1dhigh IgDlow/ IgMhigh;
Fo1: CD19+ CD93 CD21low CD23+ IgDhigh IgMlow; Fo2: CD19+ CD93 CD21low CD23+ IgDhigh IgMhigh; GC: CD19+ CD43 CD24+ GL7+.
Cell populations were initially selected on the basis of ‘Lymphocyte’ size (forward scatter; FSC) and granularity (side scatter; SSC) parameters
and excluding ‘doublets’ (by comparing FSC-Height and FSC-Area) and dead cells (by the Live/Dead fixable aqua dead cell dye; Invitrogen)
(data not shown). We initially gated on CD19+ CD23 and CD19+ CD23+ cells (a) to resolve MZP (CD21high CD1dhigh) from follicular (Fo)
(CD21low CD1dlow) B cells (b) and MZ (CD21+ IgM+) and T1 (CD21 IgM+) cells (c), respectively. The Fo population identified (b;
CD21low CD1dlow) is a heterogeneous population that contains the functionally distinct follicular type 1 (Fo1: IgDhigh IgMlow AA41) and follic-
ular type 2 (Fo2: IgDhigh IgMhigh AA41) as well as the transitional 2 (T2: IgDhigh IgMhigh AA41+) and transitional 3 (T3:
IgDhigh IgMlow AA41+) populations. These populations are first separated on the basis of their expression of IgM and IgD (d) and then, AA41
(e,f). For the identification of germinal centre (GC) B cells we first identify CD19+ CD43 cells (g) and then exclude contaminating non-B cells
by gating on the GC cell-specific marker GL7 along with the pan-B-cell marker CD24 (h) before confirming expression of FAS (i) by essentially
all (> 90%) CD19+ CD43 CD24+ GL7+ GC B cells; we have therefore not included this redundant marker in our analysis.
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generation of pathogenic antibodies by blocking the activa-
tion of follicular B cells and their consequent differentia-
tion into GC B cells.15
ES-62 modulates the recruitment of B cells to the
joints of mice with CIA
As pathogenic B cells migrate to the joints and even form
ectopic GCs in response to B-cell recruitment and sur-
vival factors such as BAFF, CXCL12 and CXCL13 secreted
by synovial fibroblasts,5 we next analysed whether the
above effects of in vivo exposure to ES-62 on the profile
of B cells were reflected in the arthritic joint. This
revealed that both the proportion (Fig. 3a,b) and absolute
numbers (Fig. 3c) of CD19+ B cells found in the joints
were significantly reduced by ES-62 treatment. This
reduction was reflected in a CD19+ CD23+ B-cell popula-
tion (Fig. 3d,e), which further analysis revealed to be Fo1
B cells (Table 1). There was also a clear decrease in
CD19 CD138+ (from 927 to 245% live cells) and
CD19+ CD138+ (from 156 to 451% live cells) cells infil-
trating the joints of mice treated with ES-62 (Fig. 3f,g),
which suggested a reduction in plasma cells. Consistent
with this, further analysis, excluding the myeloid and T-cell
lineages expressing CD138 (Fig. 3h), revealed that exposure
to ES-62 indeed suppressed the proportions (Fig. 3i, j) and
numbers (Table 1) of CD19 B220 CD138+ (from 831
to 369% live cells) and CD19+ B220low/ CD138+ (from
137 to 072% live cells) plasma cells, which respectively are
phenotypically similar to the long-lived plasma cell and
short-lived plasma cell/plasmablast functional populations,
reported previously.16–18 This presumably reflects reduced
development and/or migration of such cells, as suggested
by the significant increases in the levels of Fo1 (Fig. 2e)
and CD19 B220 CD138+ plasma cells (numbers
(9 106)  SEM: Naive, 075  022; PBS, 128  031;
ES-62, 158  026) found in the spleen, as ES-62 did not
modulate the levels of early CD19+ B220+ CD138+ ‘pre-
plasma cells’, which have been reported as being subject to
a tolerance checkpoint that is defective in the autoim-
mune-prone MRL/Lpr mouse19 (results not shown).
In addition to investigation of modulation of the levels
of B cells found in the joint, ES-62 was assessed for effects
on the functional phenotype of such infiltrating cells.
Hence, although ES-62 did not significantly modulate the
expression of BAFF-R, CD80, CD86 or TLR4 (either in
terms of percentage positive cells or levels of expression)
on splenic CD19+ B cells, expression of CD80, TLR4 and,
to a lesser extent, CD86, but not BAFF-R, by CD19+ B cells
in the joint was down-regulated, mirroring a tendency
towards a decrease in expression of both CD80 and TLR4
by CD19+ DLN cells (results not shown). Further analysis
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Figure 2. ES-62 reduces the levels of germinal centre B cells in the spleens of mice with collagen-induced arthritis (CIA). Mean articular scores
(SEM) of CIA mice treated with PBS (n = 34) or ES-62 (n = 18) at time of cull at day 28 (a). The percentage of CD19+ B cells (b); representa-
tive plots (c) and proportions (d; mean values  SEM of individual mice where naive, n = 16; PBS, n = 31; ES-62, n = 12) of marginal zone
precursor (MZP), marginal zone (MZ) and follicular (Fo) B cells as defined by their expression of CD21 and CD23; Follicular type 1 B cells
(Fo1, e: CD19+ CD23+ CD21low CD1dlow IgMlow IgDhigh AA41) and germinal centre cells (GC; f: CD19+ CD43 CD24+ GL7+), as derived by
the gating strategy presented in Fig. 1, in spleens from mice undergoing CIA are shown.
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revealed that this reflected selective down-regulation of
TLR4, CD80 and CD86 expression on CD19+ CD23high
CD21low Fo B cells but not CD19+ CD23 CD21high or
CD19+ CD23high CD21high B cells (Fig. 4 and results not
shown). Moreover, although B1, GC and plasma cells also
expressed TLR4, such expression was not modulated by
exposure to ES-62 (results not shown).
Collectively, therefore, these data suggest that ES-62
may act to prevent development and migration of patho-
genic B cells to the site of inflammation, with the residual
B cells that infiltrate the joint being rendered functionally
hyporesponsive.
ES-62 restores the levels of IL-10-producing B cells in
the spleen of mice with CIA
Interleukin-10-producing B cells that exhibit regulatory
activity (Breg cells) have been reported to curb patho-
genic Th1/Th17 responses in CIA and it has been
proposed that these cells protect against disease by promot-
ing the development of Tr1 cells.6 Although the ES-62-
mediated suppression of B-cell development and migration
(Figs 2 and 3) and consequent inhibition of generation of
pathogenic IgG2a responses observed in CIA11 might
reflect the ability of the parasitic worm product to induce
hyporesponsiveness of B2 cells by uncoupling the B-cell
receptor from extracellular signal regulated kinase/mito-
gen-activated protein kinase signalling, both in vitro and
in vivo,20,21 it is also interesting to note that ES-62 has pre-
viously been shown to induce the production of IL-10 by
peritoneal B1 B cells.22 As B1 cells are not thought to play a
central role in systemic autoimmunity and autoantibody
production in CIA,23 it is therefore possible that the
reduced levels of CD19+ IgM+ CD43high CD5+ and
CD19+ IgM+ CD43high CD5 cells, which have been
reported to be B1a and B1b cells, respectively,24–28 found in
the spleens (Fig. 5a–c) and DLNs (Fig. 5d) of ES-62-trea-
ted mice with CIA could reflect their egress and migration
Table 1. Exposure to ES-62 in vivo suppresses infiltration of the joints by B2 cells and plasma cells
Group CD19+ B220low/ CD138+ CD19 B220 CD138+ Fo1
Exp 1 2 1 2 1 2
PBS 024 067 15 074 0029 011
ES-62 0035 032 018 036 0009 0033
Data (number of cells 9 106) are presented from two independent experiments where CD19+ B220low/ CD138+ and CD19 B220 CD138+
plasma cell and CD19+ CD21low CD23+ AA41 IgMlow IgDhigh Fol B-cell populations infiltrating the joints were analysed by flow cytometric
analysis of joint cells harvested from six or seven mice from each group.
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Figure 3. ES-62 modulates the recruitment of B cells to the joints of mice with collagen-induced arthritis (CIA). Cells extracted from the joints
of mice with CIA were analysed for the proportion (a,b) and number (c) of infiltrating CD19+ B cells (data in c are presented as the
means  SEM of four biological replicates pooled from two independent experiments) and consequently for the relative proportions of
CD19+ CD23+ (d,e) and plasma cells on the basis of CD19 CD138 expression (f,g). Exclusion of myeloid and T-cell-expressing CD138 cells
by use of Dump channel (CD4+ CD8+ GR1+ F4/80+ CD11b+ CD11c+; h) allowed analysis of Dump CD19 B220 CD138+ and
Dump CD19+ B220low/ CD138+ plasma cells (i,j).
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to the joints to mediate IL-10-dependent anti-inflamma-
tory effects. Perhaps consistent with this, although the lev-
els of B cells infiltrating the joint overall were reduced
following treatment with ES-62, the proportion of such B1-
like cells was slightly increased (PBS: 142%, 13%; ES-62:
158%, 151%, where data are expressed as the proportion
(%) of live cells, that are CD43+ CD19+ IgM+ B1-like cells,
harvested from the joints of six or seven mice/group in two
independent experiments).
Analysis of IL-10-producing B cells (Fig. 6a,b) revealed
that although induction of CIA resulted in a significant
reduction in the levels of IL-10-producing B cells, relative
to naive mice, this was not the case for those treated with
ES-62 (Fig. 6c). Indeed, exposure to ES-62 led to a signif-
icant enhancement in the level of IL-10-producing B cells
in mice with CIA, restoring them to levels comparable
with those found in healthy naive mice [Fig. 6c; numbers
(9 106)  SEM: Naive, 181  022; PBS, 148  012;
ES-62, 199  026]. CD19+ IL-10+ B cells in the spleens
of naive and CIA mice reflected a mixed population com-
prising phenotypes consistent with marginal zone precur-
sor, marginal zone, follicular B cells and CD19+ CD21
CD23 B cells (Fig. 6b): almost all of these cells expressed
CD1d whereas some 20–30% of the follicular and
CD19+ CD21 CD23 B cells expressed CD5 (data not
shown), the latter a marker previously associated with
certain IL-10-producing B cells.29,30 Rather surprisingly,
the ability of ES-62 to return the levels of IL-10-produc-
ing B cells towards that existing in naive, non-arthritic
mice, did not appear to involve a preferential modulation
of any of these phenotypes, perhaps suggesting that it acts
rather to regulate B-cell responses in a ‘homeostatic’
manner. Although the protective effects of IL-10-produc-
ing B cells in CIA have previously been reported to be
associated with the induction of Tr1 cells,6 our analysis
showed the IL-10 production by splenocytes to be pre-
dominantly B-cell-derived (Fig. 6a) and that the
CD19 IL-10+ population was not increased by treatment
with ES-62 (Fig. 6d), suggesting that Tr1 cells were not
being induced in this case. Likewise, and consistent with
the previously reported lack of Breg-mediated induction
of Treg cells in the CIA model,6 further investigation
indicated that in vivo treatment with ES-62 did not result
in enhanced levels of FoxP3-expressing CD4+ Treg cells
in the DLN (results not shown), as shown following
induction of Breg cells in AIA.31
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Discussion
The successful clinical implementation of B-cell depletion
therapies in recent years has reignited interest in the
pathogenic and protective roles of B cells in RA. In par-
ticular, much interest has focused on the ability of IL-10-
producing Breg cells to prevent development of patho-
genic Th1/Th17 responses and to induce Treg cells that
result in the suppression of disease in the AIA (induced
by methylated BSA) and CIA mouse models of RA.6,8,31
Interestingly, therefore it has recently emerged that one of
the strategies exploited by parasitic helminths to dampen
host immune responses and hence promote their survival
is the induction of IL-10-producing Breg cells: moreover,
the protection afforded against allergic inflammatory dis-
ease by such worms has also been associated, at least in
part, with their induction of such Breg cells.28,32–35
Hence, our current findings that exposure to ES-62
results in elevated levels of IL-10-producing B cells may
provide a rationale for our previous findings that the par-
asite product exerts its protective effects in CIA via sup-
pression of Th1, Th17 and IL-17-producing cd T-cell
responses, as well as being consistent with our earlier
observation that it promotes spontaneous IL-10
production by splenocytes from mice with CIA.4,9,11
Interestingly, although regulatory B cells have been pro-
posed to mediate at least some of their protective effects
in experimental arthritis via the generation of natural
Treg cells (AIA) and/or induced Tr1 cells (AIA and
CIA),6,8,31 we have found no evidence that ES-62 induces
any IL-10-producing Treg cells in DBA/1 mice with CIA.
Although perhaps surprising, this failure to induce Treg
cells is supported by our preliminary data from the
C57BL/6 model of chronic CIA,36 in which in vivo expo-
sure to ES-62 does not increase the levels of either
FoxP3+ or IL-10-producing CD4+ T cells in the DLN of
such mice (results not shown) and is consistent with their
lack of induction in our previous studies investigating
ES-62-mediated hyporesponsiveness to the model antigen
ovalbumin in both the DO.11.10 transfer model37 and the
ovalbumin-induced airway inflammation model of
asthma.38 Nevertheless, we cannot rule out the possibility
that while ES-62 does not increase the levels of Treg cells
in mice with CIA, it may act to reverse/overcome the
impaired (cell contact-mediated) suppressive ability of
Treg cells reported in RA.39
Perhaps also surprisingly, the restoration of IL-10-pro-
ducing B cells resulting from exposure to ES-62 did not
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Figure 5. ES-62 modulates the levels of B1-like cells in the spleen and LNs of mice with collagen-induced arthritis (CIA). There is no unambigu-
ous phenotype for B1 cells in the spleen but they have been described as CD19high CD23 CD43+ IgMhigh IgDlow/ CD5 cells where CD5+ B1a
and CD5 B1b comprise ~2% and 1% of cells in the spleen, respectively.24 However, following gating on CD19+ IgM+ (a), analysis of
CD43+ CD5 cells has been widely used to describe B1 cells25,26 whereas CD19+ CD5+ gating has been used to describe B1a cells.28 Moreover,
although CD43 can be up-regulated on B2 cells, this is usually expressed at a lower level than on B1 cells27 and we have therefore chosen to gate
only on CD43high cells (b) so as to exclude any potential CD43+ B2 cells. We have therefore phenotyped CD19high CD43+ IgMhigh B cells as
CD5+ B1a-like cells and CD5 B1b-like cells and the data show their relative proportions in the spleen (c; naive, n = 10; PBS, n = 13 and ES-62,
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reflect induction of a particular phenotype of B cells asso-
ciated with regulatory function: although modest, these
statistically significant increases in IL-10-producing B cells
are consistent with the numbers seen in other studies in
the absence of enrichment by anti-CD40 or lipopolysac-
charide/IL-21 stimulation12,40,41 and suggest that ES-62
may be acting in a homeostatic manner to reset the bal-
ance of effector and regulatory B cells back towards that
observed in healthy DBA/1 mice. However, although the
ES-62-mediated suppression of the level of GC B cells
was associated with a reduction of follicular helper T
cells, our preliminary data suggest that the residual follic-
ular helper T cells produced slightly higher levels of the
cytokine IL-21, which appears to be critical for the gener-
ation of functional Breg cells that combat autoimmuni-
ty.41 Hence, as we have not formally demonstrated the
regulatory function of these IL-10-producing B cells, we
cannot rule out the possibility at this stage that ES-62 is
also reversing the defective regulatory function of one or
more Breg phenotypes observed in CIA and also in RA
patients.42,43 Nevertheless, we have shown previously that
whereas ES-62 induces high levels of IgG1, but not IgG2a,
antibodies in naive wild-type BALB/c mice, in IL-10/
mice the helminth product induces both IgG1 and IgG2a
antibodies. This suggests that IL-10 plays an important
role in the suppression of IgG2a antibodies directed
against ES-62.44 Interestingly, therefore, we have shown
that neither the ES-62-mediated suppression of DC-prim-
ing of OVA-specific Th1 responses45 nor the suppression
of TLR-mediated IL-12 responses of macrophages
exposed to ES-62 either in vitro or in vivo46 is due to
autocrine production of IL-10 by APC. By contrast,
although we have shown that exposure to ES-62 in vivo
induces hyporesponsiveness of splenic B2 cells, peritoneal
B cells from such mice produced enhanced spontaneous
and B-cell receptor-stimulated IL-10 responses21,22 and
although these peritoneal cells will predominantly com-
prise B1 cells, there is increasing evidence that they prob-
ably also include some B2 cells.27
Collectively, therefore, these data suggest that exposure
to ES-62 leads to hyporesponsiveness of effector B2-cell
responses and restoration of IL-10-producing B cells
that in CIA, given the complex interplay between
B-cell-derived IL-10 and pathogenic IL-17 responses in
the regulation of inflammation and autoantibody
responses,6,12,31,41,47–49 results in the reduction of plasma
cells that may contribute to the suppression of pathogenic
autoantibodies and inflammation associated with the pro-
tection against CIA. For example, the ability of B-cell-
derived IL-10 to impact on antigen-presenting cells such
as dendritic cells in vivo may contribute to the effects of
ES-62 on the DC-dependent priming of Th1/Th17 and
IL-17-producing cd T cells.4,38,45 Alternatively, such IL-10
may suppress effector B-cell activation with consequent
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Figure 6. ES-62 induces interleukin-10 (IL-10)-producing B cells in the spleen of mice with collagen-induced arthritis (CIA). IL-10-producing
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induction of T-cell hyporesponsiveness, as the reduction
of GC B cells and follicular helper T cells observed in the
spleens of ES-62-treated mice is reminiscent of that
reported for mast cell-derived IL-10-mediated suppression
of follicular helper T-cell function.50 This could be partic-
ularly important at the site of inflammation with the pro-
found down-regulation of CD80 and CD86 expression on
follicular B cells impacting on the functionality of ectopic
GCs given that expression of CD80 by B cells has been
shown to be important in the regulation of follicular
helper T-cell development, and consequent GC B-cell sur-
vival and plasma cell production,51 the latter population
being clearly reduced in the joints of ES-62-treated mice.
Interestingly therefore, blocking of B7–CD28 interactions
has been reported to be sufficient to prevent development
of CIA.52 Finally, the strong down-regulation of TLR4 is
similarly likely to suppress B-cell activation and plasma
cell generation at this site,53 and in this way, disrupt the
destructive chronic inflammation resulting from cells in
the joint expressing up-regulated levels of TLRs, including
TLR454 and responding to damage-associated molecular
pattern molecules, such as heat-shock protein 22 and
tenascin-C55 found in the synovium of RA patients.
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